Bay­er wins OK for he­mo­phil­ia A treat­ment; Agenus sells off a slice of fu­ture roy­al­ties for $15M

→ Japan­ese of­fi­cials have ap­proved Bay­er’s he­mo­phil­ia A drug Jivi (BAY94-9027), a Fac­tor VI­II treat­ment.

→ Xo­ma is tap­ping in­to their line of cred­it at Sil­i­con Val­ley Bank to help pay a $15 mil­lion tab to buy in­to Agenus’ roy­al­ty stream due for its li­cens­ing rights to im­muno-on­col­o­gy drugs be­ing de­vel­oped by Mer­ck and In­cyte. “This is an im­por­tant deal re­flect­ing our new roy­al­ty-ag­gre­ga­tor strat­e­gy to ac­quire mile­stone and roy­al­ty pay­ments as­so­ci­at­ed with ther­a­peu­tic can­di­dates part­nered by oth­ers,” said Xo­ma CEO Jim Neal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER